Patents by Inventor Laureano Simon
Laureano Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11578368Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.Type: GrantFiled: April 28, 2020Date of Patent: February 14, 2023Assignee: Patia Biopharma, S.A. De C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta
-
Publication number: 20220213084Abstract: The present invention refers to oxadiazole compounds suitable as HDAC6 inhibitors. Processes for their preparation and their medical uses in treating HDAC6-related diseases or disorders are also disclosed.Type: ApplicationFiled: April 16, 2020Publication date: July 7, 2022Inventors: Yosu Ion VARA SALAZAR, Eneko ALDABA ARÉVALO, Tamara BELLO IGLESIAS, Richard Spurring ROBERTS, Laureano SIMÓN BUELA, José Manuel BREA, Ángel CARRACEDO, María Isabel LOZA GARCÍA
-
Patent number: 11085082Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.Type: GrantFiled: December 16, 2016Date of Patent: August 10, 2021Assignee: Patia Biopharma S.A. de C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
-
Patent number: 10864278Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: October 16, 2018Date of Patent: December 15, 2020Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Publication number: 20200318192Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.Type: ApplicationFiled: April 28, 2020Publication date: October 8, 2020Applicant: Patia Biopharmia, S.A. De C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta
-
Publication number: 20200283850Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.Type: ApplicationFiled: December 16, 2016Publication date: September 10, 2020Applicant: Patia Biopharma, S.A. de C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
-
Publication number: 20190105406Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p ??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: ApplicationFiled: October 16, 2018Publication date: April 11, 2019Applicant: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 10215762Abstract: The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.Type: GrantFiled: September 30, 2016Date of Patent: February 26, 2019Assignee: Progenika Biopharma, S.A.Inventors: Ainhoa Ruiz Del Agua, Antonio Martinez Martinez, Daniel Nagore Casas, Laureano Simon Buela
-
Patent number: 10137202Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: February 4, 2015Date of Patent: November 27, 2018Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 10004812Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: February 4, 2015Date of Patent: June 26, 2018Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Publication number: 20180094318Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11—rs75493593; HNF1A—rs483353044; TCF7L2—rs7903146; CDKN2A/B—rs10811661; CDKAL1—rs7756992; SLC30A8—rs3802177; IGF2BP2—rs4402960; FTO—rs9936385; PPARG—rs1801282; HHEX/IDE—rs1111875; ADCY5—rs11717195; JAZF1—rs849135; WSF1—rs4458523; INS—IGF2—rs149483638; KCNQ1—rs2237897; and KCNJ11—rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.Type: ApplicationFiled: March 18, 2016Publication date: April 5, 2018Applicant: Patia Biopharmia, S.A. De C.V.Inventors: Laureano Simón Buela, Mirella G. Zulueta
-
Patent number: 9702879Abstract: The present invention relates to in vitro methods and products for detecting the presence of an invasive carcinoma in an individual, for determining and/or predicting the stage and/or invasiveness of said carcinoma in an individual, or for monitoring the effect of the therapy administered to an individual who has said carcinoma based on col11a1 gene and proCOL11A1 protein expression. The invention also relates to the search for, identification, development and evaluation of the efficacy of compounds for therapy for said carcinoma, for the purpose of developing new medicinal products. The invention also relates to agents inhibiting proCOL11A1 protein expression and/or activity, and/or the effects of this expression.Type: GrantFiled: August 8, 2012Date of Patent: July 11, 2017Assignee: Oncomatryx Biopharma, S.L.Inventors: Luis Barneo Serra, Carmen Garcia Pravia, Juan Ramon De Los Toyos Gonzalez, Marcos Garcia Ocana, Jose Fernando Vazquez Villa, Nelson Fuentes Martinez, Jokin Del Amo Iribarren, Laureano Simon Buela
-
Patent number: 9637788Abstract: The present invention provides a method for detecting the presence or absence of, or for discriminating between, blood type variants, including RHD*r?s, RHD*DIIIa, RHD*DIVa-2, RHCE*css and RHCE*ce733G. The method comprises genotyping a sample obtained from a human subject at one or more positions in intron 7 of the RHD gene and/or in intron 7 of the RHCE gene. The invention also provides products, in particular, probes, primers and kits for use in the method of the invention.Type: GrantFiled: June 14, 2012Date of Patent: May 2, 2017Assignee: Progenika Biopharma, S.A.Inventors: Jorge Ochoa, Monica Lopez, Sergio Escorza, Diego Tejedor, Antonio Martinez, Laureano Simon
-
Publication number: 20170102394Abstract: The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.Type: ApplicationFiled: September 30, 2016Publication date: April 13, 2017Applicant: PROGENIKA BIOPHARMA, S.A.Inventors: AINHOA RUIZ DEL AGUA, Antonio Martinez Martinez, Daniel Nagore Casas, Laureano Simon Buela
-
Publication number: 20170007714Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: ApplicationFiled: February 4, 2015Publication date: January 12, 2017Applicant: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Publication number: 20170007716Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: ApplicationFiled: February 4, 2015Publication date: January 12, 2017Applicant: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Publication number: 20160305963Abstract: A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.Type: ApplicationFiled: June 21, 2016Publication date: October 20, 2016Applicant: Brainco Biopharma, S.L.Inventors: David Arteta, Marcelo Ferrer, Laureano Simon, Antonio Martinez, Maria Uribarri
-
Publication number: 20160274119Abstract: The present invention relates to methods and products for the diagnosis and prognosis of ovarian tumor malignancy based on proCOL11A1 protein which is expressed in malignant ovarian tumors but not in non-tumoral ovarian tissue or in situ or benign or borderline ovarian tumors. proCOL11A1-specific antibodies can be used for high sensitivity and specificity diagnosis of ovarian cancer as well as for differentiating malignant ovarian tumors from benign or in situ tumors, and for the prognosis of ovarian tumor malignancy and for predicting borderline tumor malignancy. The invention has application in in vitro methods for the diagnosis and prognosis of ovarian tumor malignancy.Type: ApplicationFiled: October 1, 2014Publication date: September 22, 2016Applicant: Oncomatrix, S.L.Inventors: Saioa Dominguez Hormaetxe, Laureano Simon Buela
-
Patent number: 9398761Abstract: A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.Type: GrantFiled: March 14, 2013Date of Patent: July 26, 2016Assignee: Brainco Biopharma, S.L.Inventors: David Arteta, Marcelo Ferrer, Laureano Simon, Antonio Martinez, Maria Uribarri
-
Publication number: 20160060696Abstract: The invention relates to genotyping and blood cell antigen determination. In particular, the invention addresses discriminating the RHD*DIIIa-CE(4-7)-D or RHD*DIIIa-CE(4-7)-D)-like blood type variants, from RHD*DIIIa, RHD*DIVa-2 and other blood type variants. The invention provides methods for genotyping a subject, comprising determining at least 4 markers in a sample that has been obtained from the subject, wherein the markers comprise: (i) the presence or absence of an RHCE*C allele; (ii) the presence or absence of an RHD/RHCE hybrid exon 3 (RHD/CE Hex03) allele; (iii) the absence of, or a single nucleotide polymorphism (SNP) variant within, any one of position 602 of exon 4, position 667 of exon 5, or position 819 of exon 6 of RHD; and (iv) the absence of, or SNP variant within, position 1048 of RHD exon 7. The invention also provides probes, primers and kits for use in such methods.Type: ApplicationFiled: November 11, 2015Publication date: March 3, 2016Applicant: PROGENIKA BIOPHARMA, S.A.Inventors: Jorge Ochoa, Monica Lopez, Diego Tejedor, Antonio Martinez, Laureano Simon